FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119321309> ?p ?o ?g. }

• W2119321309 endingPage "565" @default.
• W2119321309 startingPage "557" @default.
• W2119321309 abstract "Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib. However, these drugs have little effect on brain metastasis due to the combined effects of poor penetration of the blood-brain barrier and their removal from the central nervous system (CNS) by the p-glycoprotein (Pgp) drug efflux pump. We investigated the effects of TAK-285, a novel, investigational, dual EGFR/HER2 inhibitor that has been shown to penetrate the CNS and has comparable inhibitory efficacy to lapatinib which is a known Pgp substrate. Tested against a panel of 96 kinases, TAK-285 showed specificity for inhibition of HER family kinases. Unlike lapatinib, TAK-285 is not a substrate for Pgp efflux. In mouse and rat xenograft tumor models, TAK-285 showed antitumor activity against cancers that expressed HER2 or EGFR. TAK-285 was as effective as lapatinib in antitumor activity in a mouse subcutaneous BT-474 breast cancer xenograft model. TAK-285 was examined in a model of breast cancer brain metastasis using direct intracranial injection of BT-474-derived luciferase-expressing cells and showed greater inhibition of brain tumor growth compared to animals treated with lapatinib. Our studies suggest that investigational drugs such as TAK-285 that have strong antitumor activity and are not Pgp substrates may be useful in the development of agents with the potential to treat brain metastases." @default.
• W2119321309 created "2016-06-24" @default.
• W2119321309 creator A5004487823 @default.
• W2119321309 creator A5029811349 @default.
• W2119321309 creator A5040800538 @default.
• W2119321309 creator A5063218965 @default.
• W2119321309 creator A5065272096 @default.
• W2119321309 creator A5068430981 @default.
• W2119321309 creator A5071502849 @default.
• W2119321309 creator A5075554308 @default.
• W2119321309 creator A5081849159 @default.
• W2119321309 date "2013-01-01" @default.
• W2119321309 modified "2023-09-26" @default.
• W2119321309 title "Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model" @default.
• W2119321309 cites W1505543021 @default.
• W2119321309 cites W1886326176 @default.
• W2119321309 cites W1974024530 @default.
• W2119321309 cites W1980212553 @default.
• W2119321309 cites W1987820290 @default.
• W2119321309 cites W1991942241 @default.
• W2119321309 cites W2001790582 @default.
• W2119321309 cites W2009927285 @default.
• W2119321309 cites W2015534267 @default.
• W2119321309 cites W2022050818 @default.
• W2119321309 cites W2039297169 @default.
• W2119321309 cites W2050156776 @default.
• W2119321309 cites W2057151160 @default.
• W2119321309 cites W2103484524 @default.
• W2119321309 cites W2111257721 @default.
• W2119321309 cites W2139085578 @default.
• W2119321309 cites W2144381567 @default.
• W2119321309 cites W2144686284 @default.
• W2119321309 cites W2149927715 @default.
• W2119321309 cites W2152528081 @default.
• W2119321309 cites W2155974380 @default.
• W2119321309 cites W2564005606 @default.
• W2119321309 cites W1590093102 @default.
• W2119321309 doi "https://doi.org/10.7150/jca.6689" @default.
• W2119321309 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3753530" @default.
• W2119321309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23983820" @default.
• W2119321309 hasPublicationYear "2013" @default.
• W2119321309 type Work @default.
• W2119321309 sameAs 2119321309 @default.
• W2119321309 citedByCount "18" @default.
• W2119321309 countsByYear W21193213092013 @default.
• W2119321309 countsByYear W21193213092014 @default.
• W2119321309 countsByYear W21193213092015 @default.
• W2119321309 countsByYear W21193213092016 @default.
• W2119321309 countsByYear W21193213092017 @default.
• W2119321309 countsByYear W21193213092018 @default.
• W2119321309 countsByYear W21193213092019 @default.
• W2119321309 countsByYear W21193213092020 @default.
• W2119321309 countsByYear W21193213092021 @default.
• W2119321309 countsByYear W21193213092022 @default.
• W2119321309 countsByYear W21193213092023 @default.
• W2119321309 crossrefType "journal-article" @default.
• W2119321309 hasAuthorship W2119321309A5004487823 @default.
• W2119321309 hasAuthorship W2119321309A5029811349 @default.
• W2119321309 hasAuthorship W2119321309A5040800538 @default.
• W2119321309 hasAuthorship W2119321309A5063218965 @default.
• W2119321309 hasAuthorship W2119321309A5065272096 @default.
• W2119321309 hasAuthorship W2119321309A5068430981 @default.
• W2119321309 hasAuthorship W2119321309A5071502849 @default.
• W2119321309 hasAuthorship W2119321309A5075554308 @default.
• W2119321309 hasAuthorship W2119321309A5081849159 @default.
• W2119321309 hasBestOaLocation W21193213091 @default.
• W2119321309 hasConcept C114851261 @default.
• W2119321309 hasConcept C121608353 @default.
• W2119321309 hasConcept C126322002 @default.
• W2119321309 hasConcept C133936738 @default.
• W2119321309 hasConcept C2777329042 @default.
• W2119321309 hasConcept C2777506169 @default.
• W2119321309 hasConcept C2778164965 @default.
• W2119321309 hasConcept C2778707650 @default.
• W2119321309 hasConcept C2779013556 @default.
• W2119321309 hasConcept C2779438470 @default.
• W2119321309 hasConcept C2779786085 @default.
• W2119321309 hasConcept C502942594 @default.
• W2119321309 hasConcept C530470458 @default.
• W2119321309 hasConcept C71924100 @default.
• W2119321309 hasConcept C86803240 @default.
• W2119321309 hasConcept C89423630 @default.
• W2119321309 hasConcept C98274493 @default.
• W2119321309 hasConceptScore W2119321309C114851261 @default.
• W2119321309 hasConceptScore W2119321309C121608353 @default.
• W2119321309 hasConceptScore W2119321309C126322002 @default.
• W2119321309 hasConceptScore W2119321309C133936738 @default.
• W2119321309 hasConceptScore W2119321309C2777329042 @default.
• W2119321309 hasConceptScore W2119321309C2777506169 @default.
• W2119321309 hasConceptScore W2119321309C2778164965 @default.
• W2119321309 hasConceptScore W2119321309C2778707650 @default.
• W2119321309 hasConceptScore W2119321309C2779013556 @default.
• W2119321309 hasConceptScore W2119321309C2779438470 @default.
• W2119321309 hasConceptScore W2119321309C2779786085 @default.
• W2119321309 hasConceptScore W2119321309C502942594 @default.
• W2119321309 hasConceptScore W2119321309C530470458 @default.
• W2119321309 hasConceptScore W2119321309C71924100 @default.
• W2119321309 hasConceptScore W2119321309C86803240 @default.

• next